{
    "root": "82e7bcd6-ebe3-4e29-85c5-f01c901ee0a1",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Zembrace SymTouch",
    "value": "20250228",
    "ingredients": [
        {
            "name": "Sumatriptan Succinate",
            "code": "J8BDZ68989",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_64359"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26710"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        }
    ],
    "indications": {
        "text": "zembrace symtouch indicated acute treatment migraine without aura adults .",
        "doid_entities": [
            {
                "text": "migraine (DOID:6364)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6364"
            },
            {
                "text": "migraine without aura (DOID:12783)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12783"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "subcutaneous . ( 2.1 ) acute treatment migraine : 3 mg single dose . ( 2.1 ) maximum dose 24-hour period : 12 mg. separate doses least 1 hour . ( 2.1 )",
        "doid_entities": [
            {
                "text": "migraine (DOID:6364)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6364"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "zembrace symtouch injection contraindicated patients : ischemic coronary artery disease ( cad ) ( angina pectoris , history myocardial infarction , documented silent ischemia ) coronary artery vasospasm , including prinzmetal 's angina [ ( 5.1 ) ] . wolff-parkinson-white syndrome arrhythmias associated cardiac accessory conduction pathway disorders [ ( 5.2 ) ] . history stroke transient ischemic attack ( tia ) history hemiplegic basilar migraine patients higher risk stroke [ ( 5.4 ) ] . peripheral vascular disease [ ( 5.5 ) ] . ischemic bowel disease [ ( 5.5 ) ] . uncontrolled hypertension [ ( 5.8 ) ] . recent ( i.e . , within 24 hours ) ergotamine-containing medication , ergot-type medication ( dihydroergotamine methysergide ) , another 5-hydroxytryptamine1 ( 5-ht1 ) agonist [ ( 7.1 , 7.3 ) ] . concurrent mao-a inhibitor recent ( within 2 weeks ) mao-a inhibitor [ ( 7.2 ) pharmacology ( 12.3 ) ] . known hypersensitivity sumatriptan ( angioedema anaphylaxis seen ) [ ( 5.9 ) ] . severe hepatic impairment [ pharmacology ( 12.3 ) ] .",
    "indications_original": "ZEMBRACE SymTouch is indicated for the acute treatment of migraine with or without aura in adults.",
    "contraindications_original": "For subcutaneous use only. ( 2.1 ) Acute treatment of migraine: 3 mg Single dose. ( 2.1 ) Maximum dose in a 24-hour period: 12 mg. Separate doses by at least 1 hour. ( 2.1 )",
    "adverseReactions_original": "ZEMBRACE SymTouch injection is contraindicated in patients with:\n                  \n                     Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal's angina [see Warnings and Precautions (5.1)].\n                     Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions (5.2)].\n                     History of stroke or transient ischemic attack (TIA) or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke [see Warnings and Precautions (5.4)]. \n                     Peripheral vascular disease [see Warnings and Precautions (5.5)].\n                     Ischemic bowel disease [see Warnings and Precautions (5.5)].\n                     Uncontrolled hypertension [see Warnings and Precautions (5.8)].\n                     Recent (i.e., within 24 hours) use of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7.1, 7.3)].\n                     Concurrent administration of an MAO-A inhibitor or recent (within 2 weeks) use of an MAO-A inhibitor [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)].\n                     Known hypersensitivity to sumatriptan (angioedema and anaphylaxis seen) [see Warnings and Precautions (5.9)].\n                     Severe hepatic impairment [see Clinical Pharmacology (12.3)].",
    "drug": [
        {
            "name": "Zembrace SymTouch",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_64359"
        }
    ]
}